SCHEMBL16396172

SCHEMBL16396172

COc1ccc(S(=O)(=O)c2cccc(N)c2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.69
PKM P14618 4/20 0.66
GAA P10253 1/20 0.56
ALDH1A1 P00352 2/20 0.53
CYP3A4 P08684 1/20 0.53
CA2 P00918 3/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA4 P22748 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
TDP1 Q9NUW8 2/20 0.50
RAPGEF4 Q8WZA2 1/20 0.50
PLAU P00749 1/20 0.50
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.50
F2 P00734 1/20 0.49
PRSS1 P07477 1/20 0.49
PRSS2 P07478 1/20 0.49
PRSS3 P35030 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9155427 0.88 LMNA (0.71) LMNAPKMGAAALDH1A1CYP3A4
SCHEMBL14441349 0.87 PKM (0.58) LMNAPKMGAAALDH1A1CYP3A4
SCHEMBL1100221 0.87 LMNA (0.91) LMNAPKMGAAALDH1A1CYP3A4
SCHEMBL12325401 0.86 PKM (0.70) LMNAPKMGAACA2TDP1
SCHEMBL8865965 0.85 LMNA (0.56) LMNAPKMALDH1A1CYP3A4CA2
SCHEMBL16168883 0.84 HTT (0.54) LMNAPKMGAAALDH1A1CYP3A4
SCHEMBL34500 0.83 LMNA (0.83) LMNAPKMALDH1A1CYP3A4CA2
Dapsone SCHEMBL26667340 0.83 LMNA (0.83) LMNAPKMALDH1A1CYP3A4CA2
SCHEMBL8721954 0.83 LMNA (0.83) LMNAPKMALDH1A1CYP3A4CA2
SCHEMBL29692583 0.83 LMNA (0.83) LMNAPKMALDH1A1CYP3A4CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10562912-B2 Heterocyclic derivatives and use thereof C&C RESEARCH LABORATORIES (KR) 2020-02-18 US disclosed
EP-3004057-B1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS C&C RES LAB (KR) 2018-07-25 EP disclosed
US-20160108056-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RESEARCH LABORATORIES (KR) 2016-04-21 US disclosed
EP-3004057-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C Research Laboratories (KR) 2016-04-13 EP disclosed
WO-2014196793-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RESEARCH LABORATORIES (KR) 2014-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160108056-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF STAT3, JAK2, STAT5A LMNA 4154/4885PKM 3114/4885GAA 3188/4885
US-10562912-B2 Heterocyclic derivatives and use thereof STAT3, JAK2, STAT5A LMNA 4154/4885PKM 3114/4885GAA 3188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.